Results 41 to 50 of about 816 (186)

Thrombin Inhibitors from Different Animals [PDF]

open access: yes, 2010
Venous and arterial thromboembolic diseases are still the most frequent causes of death and disability in high-income countries. Clinical anticoagulants are inhibitors of enzymes involved in the coagulation pathway, such as thrombin and factor Xa ...
Morais-Zani, K.   +3 more
core   +3 more sources

New Advances in Biologic Treatment for Malignant Atrophic Papulosis: A Systematic Review

open access: yesDermatologic Therapy, Volume 2026, Issue 1, 2026.
Background Malignant atrophic papulosis (MAP) is the systemic subtype of Degos disease, characterized by high lethality. Currently there is no standardized treatment protocol. Steroids and immunosuppressive therapies result in limited effectiveness. Biologic treatments offer promising therapeutic potential for MAP and significantly improve prognosis ...
Jia-Wei Liu   +3 more
wiley   +1 more source

Epidemiology of Leech Infestation in Livestock and Evaluation of Phytolacca dodecanda (Endod) for Aquatic Leech Control in Selected Districts of South, Central, and North Gondar Zones, Northwest Ethiopia

open access: yesVeterinary Medicine International, Volume 2026, Issue 1, 2026.
The livestock industry in Ethiopia suffers greatly from parasites and parasitic diseases including leech infestation. Leech infestation is a serious disease of animals and occasionally humans, but it is usually ignored. A cross‐sectional study design was carried out from January 2022 to June 2022 to estimate the prevalence of leech infestation in ...
Moges Maru   +11 more
wiley   +1 more source

Improvement of Hemocompatibility in Passive Cardiovascular Implant Devices

open access: yesAdvanced Therapeutics, Volume 8, Issue 12, December 2025.
With the ever‐increasing reliance on cardiovascular devices and implants, minimizing their impact on blood is vital for their continued success. This review investigates the common methods of tackling this challenge through careful selections of material and surface modifications.
Shiyen L. Perera   +4 more
wiley   +1 more source

Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition [PDF]

open access: yes, 2012
The serpin α-1 proteinase inhibitor (API) normally only impacts the coagulation cascade through its ability to inactivate factor XIa. However, the point mutation (Met to Arg) at position 358 results in a potent thrombin inhibitor, API M358R.
Roddick, Leigh Ann C.
core  

Traditional Chinese Medicinal Leech Induces Apoptosis and Autophagy in Glioblastoma by SGK1/Caspase‐3 and PI3K/AKT/mTOR Pathway

open access: yesCNS Neuroscience &Therapeutics, Volume 31, Issue 12, December 2025.
Schematic representation of the underlying molecular mechanisms by which leech mediates apoptosis and autophagy through SGK1/Caspase‐3 and PI3K/AKT/mTOR pathways to inhibit glioblastoma. ABSTRACT Background Glioblastoma (GBM) represents the most lethal form of high‐grade glioma, with current therapeutic options proving largely ineffective. Consequently,
Shaohua Wu   +4 more
wiley   +1 more source

An Injectable Zwitterionic Hydrogels with Multiple Intermolecular Interactions for Effective Prevention of Abdominal Adhesions

open access: yesAdvanced Science, Volume 12, Issue 42, November 13, 2025.
An injectable PSA‐ZnO through multiple intermolecular including hydrogen bonds and electrostatic interactions for effectively prevents abdominal adhesions. The PSA‐ZnO hydrogel demonstrates superior wound healing promotion (≥ 95%) and more effective inhibition of scar formation compared to the commercial 3M dressing (≈80%), and prevents post‐operative ...
Na Wen   +9 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions

open access: yesMedComm, Volume 6, Issue 11, November 2025.
Summary of PCSK9 inhibitor mechanisms. PCSK9 inhibitors (PCSK9‐i) primarily lower LDL‐cholesterol (LDL‐C) by blocking PCSK9‐mediated degradation of hepatic LDL receptors (LDLR), enhancing LDL clearance. Beyond LDLR‐dependent effects, PCSK9‐i exert multiple benefits via LDLR‐independent pathways.
Jia Kuang   +3 more
wiley   +1 more source

Biochemische und pharmakokinetische Charakterisierung zweier Varianten eines neuen, auf Dipetalogastin II basierenden, chimären Thrombininhibitors [PDF]

open access: yes, 2005
Hirudin und Dipetalogastin II sind hochpotente, natürliche Thrombininhibitoren, die in der Therapie kardiovaskulärer Erkrankungen als auch in der Tumortherapie potentielle Einsatzgebiete aufweisen.
Bitter, Thomas
core  

Delayed hypersensitivity to low molecular weight heparin (LMWH) in pregnancy [PDF]

open access: yes, 2007
Heparin is currently the anticoagulant of choice for the prevention and treatment of thrombo-embolic disease in pregnancy because it does not cross the placenta [1].
jacobson, barry frank, Schapkaitz, Elise
core   +2 more sources

Home - About - Disclaimer - Privacy